The FDA has approved Gazyva for patients aged two years and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission.

The FDA has expanded the approved use of Kerendia to adults with chronic kidney disease associated with type 1 diabetes, introducing a new treatment option for this high-risk population.

Average annual compensation for US nephrologists reached $385,965 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in nephrology.

The 56-week observational findings add longer-term clinical evidence for the eculizumab biosimilar in both complement-inhibitor-naive patients and those previously treated with reference eculizumab.